Therapeutic potential of the intestinotropic hormone, glucagon-like peptide-2

Annals of Medicine

Volumn 33, Issue 4, 2001, Pages 229-235

  L'Heureux, M C ^a   Brubaker, P L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Gastrointestinal tract; GLP 2; Growth factor; Intestinal growth; Intestinal insufficiency; Physiology; Therapeutics

Indexed keywords

GLUCAGON LIKE PEPTIDE 2; GROWTH FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLITIS; CRYPT CELL; ENTERITIS; GASTROINTESTINAL TRACT; HORMONE SYNTHESIS; INTESTINE INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; RODENT; SHORT BOWEL SYNDROME;

EID: 0034991864     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890108998750     Document Type: Article

References (74)

1. Induction of intestinal epithelial proliferation by glucagon-like peptide 2
2. New frontiers in the biology of GLP-2
3. Humoral factor in intestinal adaptation
4. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in Short-Bowel patients with no colon
5. Lamprey proglucagon and the origin of glucagon-like peptides
6. Effects of fasting, refeeding, and intraluminal triglyceride on proglucagon expression in jejunum and ileum
7. Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide
8. Proprotein convertases (PC1/PC3 and PC2) in normal and neoplastic human tissues: Their use as markers of neuroendocrine differentiation
9. Processing of mouse proglucagon by recombinant prohormone convertase 1 and immunopurified prohormone convertase 2 in vitro
10. Role of prohormone convertases in the tissue-specific processing of proglucagon
11. Proglucagon processing in an islet cell line: Effects of PC1 overexpression and PC2 depletion
12. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man
13. Distribution and properties of glucagon immunoreactivity in the digestive tract of various mammals: An immunohistochemical and immunochemical study
14. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2
15. Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats
16. Role of the vagus nerve inmediating proximal nutrient-induced glucagon-like peptide-1 secretion
17. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas
18. Secretion of the intestinotropic hormone glucagon-like peptide-2 is differentially regulated by nutrients in humans
19. Structure, measurement, and secretion of human glucagon-like peptide-2
20. Stereospecific effects of fatty acids on proglucagon-derived peptide secretion in fetal rat intestinal cultures
21. Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides
22. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop
23. Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut
24. Regulation of glucagon-like peptide-1-(7-36)amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum
25. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum
26. Monounsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1
27. Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats
28. In vivo and in vitro degradation of glucagon-like peptide-2 in humans
29. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV
30. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
31. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2
32. Dipeptidyl peptidase IV inhibition enhances the intestinotropic effect of glucagon-like peptide-2 in rats and mice
33. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease
34. mRNA levels of dipeptidyl peptidase IV decrease during intestinal adaptation
35. Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice
36. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function
37. Glucagonoma syndrome demonstrating giant duodenal villi
38. 2]-GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis
39. Biological determinants of intestinotrophic properties of GLP-2 in vivo
40. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice
41. 2]glucagon-like peptide 2
42. Glucagon-like peptide 2 is a potent growth factor for small intestine and colon
43. Enterotrophic effects of glucagon-like peptide 2 are enhanced by neurotensin
44. Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo
45. The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a PKA-independent pathway
46. Glucagon-like peptide II (GLP-II) is trophic to the intestinal epithelium of intravenously and orally fed rats
47. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis
48. Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine
49. Essential roles of the gastrin and glucagon genes in the response to experimental murine colitis
50. Glucagon-like peptide-2 increases sucrase-isomaltase but not caudal-related homeobox protein-2 gene expression
51. GLP-2 augments the adaptive response to massive intestinal resection in rat
52. The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport
53. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo
54. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse
55. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs
56. Glp-1 and Glp-2 act in synergy to inhibit fasting small bowel motility in the rat
57. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2
58. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake
59. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2
60. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents
61. Structural determinants for activity of glucagon-like peptide-2
62. Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor
63. The hormonal pattern of intestinal adaptation: A major role for enteroglucagon
64. Diabetic intestinal growth adaptation and glucagon-like peptide 2 in the rat: Effects of dietary fibre
65. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon
66. Hormonal therapy for short bowel
67. Glucagon-like peptide-2 enhances intestinal function following massive small bowel resection
68. Intestinal growth adaptation andglucagon-like peptide 2 (GLP-2) in plasma and intestinal tissue following small bowel resection or ileal-jejunal transposition in rats
69. Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion
70. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2
71. Maintaining gut integrity during parental nutrition of tumor-bearing rats: Effects of glucagon-like peptide 2
72. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis
73. Glucagon-like peptide 2: A new treatment for chemotherapy-induced enteritis
74. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2